What is/are Sodium oxybate?
Sodium oxybate (INN; tradenames Xyrem and Alcover) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy, and by the FDA and Health Canada for the treatment of cataplexy associated with narcolepsy. Sodium oxybate is the sodium salt of γ-hydroxybutyric acid (GHB). Xyrem is manufactured by Jazz Pharmaceuticals in the US and Valeant Pharmaceuticals in Canada. Under the name Alcover, it is used in Italy for treatment of alcohol withdrawal and dependence.
Sodium oxybate is generally well tolerated by most patients. The most common side effects reported in clinical trials include nausea, dizziness, headache, vomiting, sleepiness, and bed-wetting. Some patients treated with sodium oxybate have also experienced moderate to significant weight loss. This may be due to the fact that sodium oxybate improves sleep architecture and increases the length of deep sleep stages, resulting in increased production of human growth hormone (HGH) and changes in energy metabolism. Serious side effects, as listed on all prescriptions of sodium oxybate, can include hallucinations, agitation, severe mental confusion, abnormal thinking, disrupted sleep, and depression.
Mechanism of action
According to the U.S. Food and Drug Administration, the precise mechanism of action for the prescription medication sodium oxybate is unknown.
This article uses material from the Wikipedia article Sodium oxybate, which is released under the Creative Commons Attribution-Share-Alike License 3.0.